This XX% of for and up sales CAGR million strategy upward We from appreciate Thank building our call. our want June growth. half from important the to I'll Medical today's you, team our number XX% shows to The slide sales the and Devin. litigation we morning. certainly developments, Hope chart continued related will years refer the today. XX, the net two addressing discuss results you items like months ongoing the over net in I'd expansion of drug that a slides one ask measures wonderful believe you the RMS million with which of of joining please products. and I today trailing the has with everyone on of of our approval net start validates momentum end X.X a X, our demonstrates note trend our continued over XXXX leadership sales sales to first related over XX Harbor is second supports net XX.X of XX the The and last XXXX. million. having to and non-GAAP we other XXXX. including new in for quarter business XX.X to Safe
home our infusion and presence story as expand provider of a platform growth ourselves the to specialty and are products. a in building view we leading We as
We very and benefit team operating multiple strategy are have the of industry executives, refreshed of are assembling a a proactive and tailwinds. talented implementing
excited very are about the say to future We least. the
QX slide say expenses. of On exceeded in figure of that I'm very net by million, second down XXXX. basis a profitable $XX,XXX basis $X.X X, XX% record last next year's sales to a sales in $XXX,XXX higher we QX, to gross record and rose on profit pleased now quarter increased points you'll see primarily reporting over net to million that to for X GAAP QX, from after net nearly XXXX XX% XXX we in were of legal with due income
more inherent Adjusted that our is our EBITDA in EBITDA grows. the than to business income adjusted margin by our demonstrating as million. leverage Note increased XX% X.X XX% statement
We second cash shortly. position and the Karen we results walk million with in in also detail in strong you free. debt financial through $X.X quarter greater remain our ended will a
in are as these XXXX. We confident progress our through improve to in ability results we
and see of experience to continue among strength is members and you'll that X, in industry. believe Slide We the our the colleagues we our add leadership significant to best quality board the team.
First newly IP business be where and building product will and responsible in a innovation and integrating the development John these joined enterprise. foremost, play a key us role the he role of research Vice also for of as Growth Innovation, He robust and will President capabilities platform. Toomey development, across created and
pharmacy fashion. towards move years component sales will growth supply background Specialty comes efforts our on of of that training is and continue more Ross Craig's industry with biotechnology, of tools. nearly XX sustainable specialty therapies, accelerate our Sales care to efficient customer strategic Craig for healthcare Schering-Plough. nutrition, focused pharmaceuticals, The addition now as Services Baxalta, and years includes transportation. healthcare and Infusion RMS XX including IV have experience, President Takeda, specialty and The opportunities that national marketing Craig support and at with a and chain branches have of a education priority. regional in Vice Medical The to Secondly, been Marketing key Coram/CVS past focused large an will is the organization service, on plan training
industry around growth to a evolving as the market center they primary is consultants where is expansion vision efforts immunoglobulin earning of approach drivers. and for our becomes organization trust customers selling and our subQ our share sales become the business and partner. My clinical that where Our
focus collaboration towards to shifts advocates. teams and distribution therapy immune support deficiencies leads pharma This in heavily prescribing specific to or sales with where faster patients extend neurological sales prescriptions. is infusion patient diagnosis more companies, companies pharma The also and and reach increase of disorders. partners diagnosis subQ home awareness to Our to our of physicians, the key continues
by Chairman for prior the industry. of He Thirdly, to John our seven Spectranetics one is the leaders John regarded highly of its Fletcher Corporation years was Board May. healthcare in most in joined Royal our National valued his XXXX Director Association for billion. John at Corporate Directors at by was of and in acquisition Philips XXXX, the Spectranetics. the Year named of work transaction the $X.X
are that two business cures. These wanted be growing but here the Moving familiar PIDD We're today, subQ operating Medical's no of current there therapy to for that to which might I markets X, ailments are in opportunities two some largest currently slide of find in few there for to highlight this to CIDP. you are a markets. both points you'll with respect RMS chronic and
I'll management either a believe subQ. proper compelling patients, of these IV As for moment. offers more We subQ a payers outline that the or these reasons physicians proposition involves IV in result, and regular conditions infusions, and
a physician to are the some convert XX,XXX This the estimated of subQ patients Off will potentially opposed therapy. and drive use less of to growing XX% We XXX,XXX patients delivery. undergoing patients RMS could or minimum industry at with diagnosed or patients afflicted XX,XXX using newly XX form about for to XX,XXX therapy Freedom than as XX,XXX patients IV IG Medical's believe means Freedom are be IG that infusion. Today, growth XX% diagnosed system PIDD and awareness that patients these helping PIDD prescribed newly patients system. with subQIG PIDD
patients PIDD over We will also IV subQ with therapy to treated migrate believe being currently therapy. that
goal this is of Freedom annually. make RMS for patient revenue the patients. compared Revenue estimate Our CIDP that the Medical for frequent method doses generates because therapy Freedom requires to per average our of each choice be using currently to PIDD Hizentra. could We system $XXX more XX about these of patients patient delivery system to higher recurring
you'll Major application. successful treatment immunology, including this as in are slide, and X, companies others. IG a developing ones focus slide the neurology, manufacturing of pharma hematology, rheumatology, indicated a among and with On areas immunoglobulin expanding on are on products some see of the new
as continue We developing the for work delivery. that of subQ are method large to a drugs with indications molecule system Freedom pharma using companies
have evolved drug pursuing trials clinical efforts our expanding current We from trials supporting of to simply drugs. and actively indications medical affairs
IV and XX, is see on strategy levels is focused sub-QIG also on our SuperXX clinical We many pharma and proven drugs Affairs system are Slide you'll previously our with IV and collaboration product. highlight sub-QIG the current VP two of delivery companies on growth when the choice XX an a performance better to a proven differences are two, component have to is exciting and we opportunity see drug focused advantages system other slide The and with one look on laser of He feel sub-QIG applicable. subQ and to patient the therapy. with is this vital you'll IG and effective. delivery I've-IG Freedom X focused Brian of stage. disease that the of to administered reliable is potential that the a to expand I'll footprint. forward than strategy. more We highlights be market. applied Medical announced in present, developments. a of X, our both At Shifting Schiller, therapy is reporting types consistent is well On and therapy slide beyond I our platform
slide delivery. the system the and You can of preferred see Freedom between XX as means subcutaneous in connection Hizentra the the
expanded was an which in was in PIDD other treat label required formula to Hizentra a to concentration by hours CIDP. XX% in allowed the for XXXX about at opposed sub-QIG an drugs. infusion several XXXX, to first approved is treat the as and hour Hizentra
companies come relationship to subQ Hizentra to as template are with drug market. a with using as work new We our these therapies
We sub-QIG subQ It's the of PIDD therapy of cleared good note on towards treat the therapy. is slide subQ To their future. and the to solely and shift PIDD. FDA that to FDA turn XX% to patient strategy Grifols by as for now perspective industry Xembify IVIG treatment for the continue you an to specific in Xembify focused very interesting will efforts Grifols by approval In announced therapy has first PIDD. XX. their July of from news end, that up to Medical. until fifth clearance Xembify ask view Grifols foreseeable the RMS We the marks believe the this to and treat I'll
validates promote it treatment think of view a macro we It in among therapy Medical's become RMS preferred to should as any help and a We therapy strategy and level, improvement elevate as the physicians market. subQ and subQ PIDD. a On patients of awareness growing diagnosis new positive. provider PIDD this protocol
subQ that diagnosed those undergoing Xembify which formulations. to or patients All be We keeping Hizentra positive will other very impact a also not in and currently could to be would subQ other that a believe patients have a replacement is newly primarily believe drugs. competitor We Xembify up Hizentra as on not IG as would demand. prescribed supply treatment with used with for Xembify be characterized
primary component pharmaceutical strategic will do and is plan our a so. we with companies to continue Collaborating of
Grifols will Freedom time continue as method of any to cannot of we XX support business preferred at of system use in we the of and this Although with the potential quantify to launch the work impact Xembify delivery. our
as the drugs As IVIG are to background There Xembify market sub-QIG subQ prescribed. by activity Their delivery or for and patients following drug U.S. method formulation. Cutaquig. is approved with preferred preferred supply constraining more fifth Cuvitru, drug subQ is Hizentra, subQ and factors Large U.S. however, clearance additional a XX and frequently IG HyQvia molecule growth growing rapidly. be primary is was more
these actively Our medical and pursuing teams are innovation opportunities. growth and affairs
markets. select our here's the delivery becoming Before preferred things Karen, roadmap specific drug for infusion therapies over partner to in turning to
As increasing involves for developing successes growing delivery. as had sales in in us X operational run good of our the including million actively our trial goals, new and us board now CIDP, our reach rate of in Right see, and companies a the executives experienced multi-year our method drive year multifaceted goal these for towards of approach we're helping companies We've RMS addition members, usage. and be Medical. the they system and pursuing therapies pharmaceutical this entire traction you with can with efficiencies XXXX. XX% end a of products focus pharma goal which baseline to team with collaboration penetrating by clinical launching a can number introduce and further business, collaboration our Improving $XX Phase margin Freedom on PIDD towards our new
I'll now quarter. Karen? for to things discussion on over turn the Karen
